If the antinuclear antibody (ANA) test is negative, is further testing for suspected secondary Sjögren’s syndrome still useful?

ANA-Negative Secondary Sjögren's: Limited Utility for Further Autoantibody Testing

In suspected secondary Sjögren's syndrome with a negative ANA, further autoantibody testing has minimal clinical utility and should generally be avoided unless clinical suspicion remains exceptionally high.

The Evidence-Based Rationale

The international guideline consensus establishes that indirect immunofluorescence assay (IIFA) for ANA is the reference first-level screening test for systemic autoimmune rheumatic diseases (SARD), including Sjögren's syndrome 1. This hierarchical approach is critical: ANA testing precedes extractable nuclear antigen (ENA) testing in the diagnostic algorithm.

Why ANA-Negative Testing Rarely Yields Diagnoses

Recent large-scale studies demonstrate that when ANA is negative but ENA testing is performed anyway, only 6-7% of patients receive a new diagnosis of ANA-associated rheumatic disease 2, 3. Specifically:

• In a 7-year Australian multicenter study of 328 patients with negative ANA but positive ENA, only 17 patients (6.09%) received a new AARD diagnosis 3
• A Turkish tertiary hospital study found similar results: among 307 patients with discordant ANA/ENA results, only 23 (7.4%) were newly diagnosed with AARD 2
• A negative ANA predicted negative subserologies with rare exceptions (only 2.2% had positive subserologies) 4

The Secondary Sjögren's Context

For secondary Sjögren's specifically, the situation is even more clear-cut. Patients with secondary Sjögren's associated with rheumatoid arthritis or systemic lupus erythematosus demonstrate mixed immunological features of both conditions 5. The autoantibody profile reflects the underlying systemic disease plus Sjögren's features—meaning if the ANA is negative, you're unlikely dealing with typical secondary Sjögren's that would benefit from further autoantibody testing.

Historical data shows that ANA/anti-ENA negative primary Sjögren's patients present with milder, later-onset disease and less frequent extraglandular manifestations 6. This pattern likely extends to secondary forms.

When to Consider Exception Testing

The guideline explicitly states: "If clinical suspicion is strong and the alternative method is negative, it is mandatory to perform IIFA" 1. This means:

• If you used a non-IIFA method initially, repeat with IIFA before abandoning ANA testing
• If IIFA-ANA remains negative but clinical features are compelling (objective sicca symptoms, parotid enlargement, characteristic imaging), consider:
  • Anti-Ro52 specifically (most common cause of ANA/ENA discordance at 19.9%) 2
  • Anti-SSA/SSB antibodies if not already tested, though yield remains low
  • Novel antibodies (anti-CA6, anti-PSP, anti-SP-1) show promise for seronegative cases but lack standardization 7

Common Pitfalls to Avoid

1. Reflexive concurrent ordering: Subspecialists are 8-fold more likely to order concurrent ANA/ENA testing 4, contributing to unnecessary costs and false-positive results
2. Ignoring anti-DFS70: This antibody (17.3% of discordant results) is associated with healthy individuals, not autoimmune disease 2
3. Misinterpreting low-titer positives: The screening dilution should be ≥1:160 to maintain specificity 1

The Practical Algorithm

For suspected secondary Sjögren's with negative ANA:

1. Confirm the ANA was performed by IIFA at appropriate dilution (≥1:160)
2. If non-IIFA method was used: Repeat with IIFA before proceeding
3. If IIFA-ANA is definitively negative:
   • Do NOT routinely order ENA panel
   • Focus on clinical diagnosis using objective sicca measures, imaging, and minor salivary gland biopsy
   • Reserve anti-Ro52/SSA testing only for patients with compelling clinical features AND where the result would change management
4. Document the underlying systemic disease (RA, SLE, etc.) as this drives the autoantibody profile more than the secondary Sjögren's component

The positive predictive value of further testing after negative ANA is too low (6-7%) to justify routine use, particularly given the risk of false-positive results leading to unnecessary patient anxiety and inappropriate treatment escalation.